Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

88% of patients with asthma and nasal polyps achieve dual remission on dupilumab

NCT ID NCT07574294

Disease control Sponsor: Azienda Ulss 2 Marca Trevigiana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 28 adults with both severe asthma and chronic sinusitis with nasal polyps who were treated with dupilumab for 24 months. The goal was to see if the drug could help control both conditions at the same time, called 'dual remission.' After 24 months, 88% of patients achieved dual remission, meaning their asthma and nasal polyps were well-controlled without needing oral steroids. However, only 32% fully recovered their sense of smell, suggesting that while the drug is very effective, smell recovery remains a challenge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

205 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with comorbid severe asthma and CRSwNP who initiated treatment with dupilumab at our Multidisciplinary Unit during the study period and met the pre-defined inclusion criteria were included in the analysis. No patients were excluded based on treatment response or clinical outcomes. All subjects were treated with dupilumab (initial dose of 600 mg followed by 300 mg every 2 weeks) as an add-on therapy. Inclusion criteria were a diagnosis of severe asthma according to GINA guidelines and concomitant CRSwNP eligible for biological treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients with comorbid severe asthma and CRSwNP who initiated treatment with dupilumab at Multidisciplinary Unit during the study period and met the pre-defined inclusion criteria ( diagnosis of severe asthma according to GINA guidelines and concomitant CRSwNP eligible for biological treatment) * Minimum age 18 years * Signature of informed consent Exclusion Criteria: * Conditions that contraindicate dupilumab therapy (eosinophilic conditions, rheumatologic conditions, helminthic infection, restrictive or interstitial lung disease) * Diagnosis of clinically significant bronchiectasis (overt diagnosis of bronchiectasis on chest CT) * Inability or lack of informed consent to participate in the study * Pregnancy * Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Chronic rhinosinusitis with nasal polyps (CRSWNP)

Contacts and locations

Locations

  • Azienda ULSS 2 Marca Trevigiana

    Montebelluna, Treviso, 31044, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.